Boehringer Ingelheim Espana S.A. — Sponsor Intelligence | 53 EU Trials

Filter these 53 trials by condition, phase, country and more.

Open in Search →

53 Registered trials

20 Recruiting

29 Completed trials

25 Countries active

32 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 15 Phase II/III: 4 Phase II: 17 Phase I/II: 1 Phase III/IV: 1 Phase I: 5 Phase I (Other): 9 Phase I (FiH): 1

Oversight events:

4 serious breaches 47 temporary halts 2 corrective measures across 12 trials

View oversight register →

100%

29 of 29 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cystic fibrosis lung 2 Obesity 2 Non-small cell lung cancer 2 Bronchiectasis 2 Portal hypertension 2 Lung adenocarcinoma 1 Pancreatic carcinoma 1 Acute myocardial infarction 1 Idiopathic pulmonary fibrosis 1 Small cell lung cancer extensive stage 1 Cystic fibrosis 1 Pustular psoriasis 1

Top IMPs

SPESOLIMAB 6 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO[3,2-D]PYRIMIDIN-4- YL]AMINO]-CYCLOBUTANEMETHANOL 4 CARBOPLATIN 4 ZONGERTINIB 4 (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID 3 BI 1015550 3 BI 1291583 3 BI 685509 3 EMPAGLIFLOZIN 3 PEMBROLIZUMAB 3 [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2-YL]METHANONE 2 ATEZOLIZUMAB 2

All trials

53 total

A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Pending

2025-521438-27-00 Phase I 4 countries
A study to find out how nerandomilast is tolerated, handled by the body, and if it helps children and adolescents with interstitial lung dis… Pending

2025-523369-32-00 Phase III 5 countries 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO…
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 Phase III 14 countries CARBOPLATIN; ETOPOSIDE; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AND CD3; TOCILIZ…
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 Phase III 20 countries ATEZOLIZUMAB; CARBOPLATIN; ETOPOSIDE; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AN…
PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Recruiting

2025-523425-17-00 Phase II 16 countries [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Recruiting

2025-523488-39-00 Phase II 7 countries BI 3000202
Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi… Recruiting

2025-523567-38-00 Phase II 3 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; ZONGERTINIB
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Phase III 15 countries [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Phase III 22 countries BI 1291583
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 Phase III 13 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; ZONGERTINIB
Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting

2023-503290-38-00 Phase II 14 countries BI 1291583
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours) Recruiting

2025-522913-45-00 Phase I (Other) 4 countries
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabe… Recruiting

2025-522953-21-00 Phase I (Other) 1 country
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Phase III 12 countries ATEZOLIZUMAB; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; ZONGERTINIB
A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting

2024-512577-27-00 Phase III 10 countries EMPAGLIFLOZIN
A study to find out whether BI 765423 has an effect on lung function in people with idiopathic pulmonary fibrosis (IPF) with or without stan… Recruiting

2025-520658-12-00 Phase II 4 countries BI 765423
A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting

2024-512849-17-00 Phase III 7 countries 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO…
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Phase III 23 countries BI 690517; EMPAGLIFLOZIN
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Phase III 11 countries SPESOLIMAB
A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting

2024-514177-21-00 Phase II 11 countries (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)…
Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting

2023-510429-14-00 Phase II 7 countries ZONGERTINIB
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 Phase III 20 countries 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO…
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes… Recruiting

2024-511246-39-00 Phase I 8 countries
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 Phase II 8 countries BI 690517; EMPAGLIFLOZIN

Showing 1–24 of 53 trials

← All sponsors A–Z